Morusin Induces Osteogenic Differentiation of Bone Marrow Mesenchymal Stem Cells by Canonical Wnt/β-catenin Pathway and Prevents Bone Loss in an Ovariectomized Rat Model

Overview

Journal Stem Cell Res Ther

Publisher Biomed Central

Date 2021 Mar 13

PMID 33712069

Citations 10

Authors

Ming Chen

Hui Han

Siqi Zhou

Yinxian Wen

Liaobin Chen

Affiliations

Soon will be listed here.

Abstract

Background: Osteoporosis (OP) is a metabolic bone disease due to the imbalance of osteogenesis and bone resorption, in which, bone marrow mesenchymal stem cells (BMSCs) have a significant effect as the seed cells. Recent research has shown the function of Morusin on inhibiting osteoclast differentiation in vitro. However, whether Morusin can regulate the osteogenic differentiation in addition to the proliferation of BMSCs remains unclear.

Methods: BMSCs were isolated from 4-week-old Wistar rats and then treated with different concentrations of Morusin for 3, 5, 7, and 14 days. The proliferation of BMSCs was detected by MTT assay. The effect of Morusin on osteogenic differentiation of BMSCs was detected by RT-qPCR, Western blotting, ALP, and Alizarin Red staining. The effect of Morusin on Wnt/β-catenin signaling pathway was analyzed by RT-qPCR, Western blotting, and immunofluorescence. Finally, in the ovariectomy-induced osteoporosis model, the anti-osteoporosis activity of Morusin was determined by micro-CT, HE, and immunohistochemistry.

Results: The results showed the function of 2.5-10 μM Morusin in the promotion of the proliferation in addition to osteogenic differentiation of BMSCs. Moreover, it also has an impact in activating the Wnt/β-catenin signaling pathway via inhibition of β-catenin phosphorylation as well as promotion of its nuclear translocation. Upon Dickkopf-related protein-1 (DKK-1, an inhibitor of the Wnt/β-catenin signaling pathway) was added to the Morusin, Morusin had a decreased stimulatory osteogenic effect on BMSCs. Finally, in the rat OP model, we found that Morusin could also exert anti-osteoporosis activity in vivo.

Conclusions: This study indicates the ability of Morusin in the promotion of osteogenic differentiation of BMSCs via the activation of Wnt/β-catenin signaling pathway and also shows the potential of Morusin to be an agent for osteoporosis treatment.

Citing Articles

MiR-223-3p Promotes Osteoporosis Progression by Repressing Osteogenic Differentiation via Targeting FHL1/Wnt/β-catenin Signaling.

Shi K, Wei J, Chen J Cell Biochem Biophys. 2024; .

PMID: 39613991 DOI: 10.1007/s12013-024-01579-0.

Targeting bone homeostasis regulation: potential of traditional Chinese medicine flavonoids in the treatment of osteoporosis.

Du J, Wang Y, Wu C, Zhang X, Zhang X, Xu X Front Pharmacol. 2024; 15:1361864.

PMID: 38628649 PMC: 11018902. DOI: 10.3389/fphar.2024.1361864.

Morusin Inhibits RANKL-induced Osteoclastogenesis and Ovariectomized Osteoporosis.

Jin C, Zheng J, Yang Q, Jia Y, Li H, Liu X Comb Chem High Throughput Screen. 2023; 27(9):1358-1370.

PMID: 37807416 DOI: 10.2174/0113862073252310230925062415.

Exploring the therapeutic and anti-tumor properties of morusin: a review of recent advances.

Hafeez A, Khan Z, Armaghan M, Khan K, Sonmez Gurer E, Razis A Front Mol Biosci. 2023; 10:1168298.

PMID: 37228582 PMC: 10203489. DOI: 10.3389/fmolb.2023.1168298.

Baicalin regulates stem cells as a creative point in the treatment of climacteric syndrome.

Wei Q, Hao X, Lau B, Wang S, Li Y Front Pharmacol. 2022; 13:986436.

PMID: 36408261 PMC: 9666758. DOI: 10.3389/fphar.2022.986436.

References

Cheng P, Hu C, Wang C, Lee Y, Chung W, Tseng T . Involvement of the antioxidative property of morusin in blocking phorbol ester-induced malignant transformation of JB6 P mouse epidermal cells. Chem Biol Interact. 2017; 264:34-42. DOI: 10.1016/j.cbi.2017.01.009. View

Cai H, Zou J, Wang W, Yang A . BMP2 induces hMSC osteogenesis and matrix remodeling. Mol Med Rep. 2020; 23(2). PMC: 7751477. DOI: 10.3892/mmr.2020.11764. View

Dempster D, Compston J, Drezner M, Glorieux F, Kanis J, Malluche H . Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 2012; 28(1):2-17. PMC: 3672237. DOI: 10.1002/jbmr.1805. View

Ducy P, Schinke T, Karsenty G . The osteoblast: a sophisticated fibroblast under central surveillance. Science. 2000; 289(5484):1501-4. DOI: 10.1126/science.289.5484.1501. View

Sun W, Shi Y, Lee W, Lee S, Long F . Rictor is required for optimal bone accrual in response to anti-sclerostin therapy in the mouse. Bone. 2016; 85:1-8. PMC: 4896354. DOI: 10.1016/j.bone.2016.01.013. View

Armas L, Recker R . Pathophysiology of osteoporosis: new mechanistic insights. Endocrinol Metab Clin North Am. 2012; 41(3):475-86. DOI: 10.1016/j.ecl.2012.04.006. View

Ahmadzadeh A, Norozi F, Shahrabi S, Shahjahani M, Saki N . Wnt/β-catenin signaling in bone marrow niche. Cell Tissue Res. 2015; 363(2):321-35. DOI: 10.1007/s00441-015-2300-y. View

Zhou D, Zheng H, Wang C, Shi D, Li J . Influence of glucocorticoids on the osteogenic differentiation of rat bone marrow-derived mesenchymal stem cells. BMC Musculoskelet Disord. 2014; 15:239. PMC: 4108975. DOI: 10.1186/1471-2474-15-239. View

Qi M, Zhang L, Ma Y, Shuai Y, Li L, Luo K . Autophagy Maintains the Function of Bone Marrow Mesenchymal Stem Cells to Prevent Estrogen Deficiency-Induced Osteoporosis. Theranostics. 2017; 7(18):4498-4516. PMC: 5695145. DOI: 10.7150/thno.17949. View

10.

Canalis E . Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches. Nat Rev Endocrinol. 2013; 9(10):575-83. DOI: 10.1038/nrendo.2013.154. View

11.

Liang T, Gao W, Zhu L, Ren J, Yao H, Wang K . TIMP-1 inhibits proliferation and osteogenic differentiation of hBMSCs through Wnt/β-catenin signaling. Biosci Rep. 2018; 39(1). PMC: 6328886. DOI: 10.1042/BSR20181290. View

12.

Zhang X, Xu H, Li G, Long M, Cheung C, Vasan R . Metabolomics Insights into Osteoporosis Through Association With Bone Mineral Density. J Bone Miner Res. 2021; 36(4):729-738. PMC: 8488880. DOI: 10.1002/jbmr.4240. View

13.

Jia Y, He W, Zhang H, He L, Wang Y, Zhang T . Morusin Ameliorates IL-1β-Induced Chondrocyte Inflammation and Osteoarthritis via NF-κB Signal Pathway. Drug Des Devel Ther. 2020; 14:1227-1240. PMC: 7105369. DOI: 10.2147/DDDT.S244462. View

14.

Zhou P, Li Y, Di R, Yang Y, Meng S, Song F . H19 and Foxc2 synergistically promotes osteogenic differentiation of BMSCs via Wnt-β-catenin pathway. J Cell Physiol. 2019; 234(8):13799-13806. DOI: 10.1002/jcp.28060. View

15.

Yang C, Luo J, Luo X, Jia W, Fang Z, Yi S . Morusin exerts anti-cancer activity in renal cell carcinoma by disturbing MAPK signaling pathways. Ann Transl Med. 2020; 8(6):327. PMC: 7186639. DOI: 10.21037/atm.2020.02.107. View

16.

Sharma A, Roberts R, Benson Jr R, Pierce J, Yu K, Hamrick M . The Senolytic Drug Navitoclax (ABT-263) Causes Trabecular Bone Loss and Impaired Osteoprogenitor Function in Aged Mice. Front Cell Dev Biol. 2020; 8:354. PMC: 7252306. DOI: 10.3389/fcell.2020.00354. View

17.

Zhang Y, Weng Q, Chen J, Han J . Morusin Inhibits Human Osteosarcoma via the PI3K-AKT Signaling Pathway. Curr Pharm Biotechnol. 2020; 21(13):1402-1409. DOI: 10.2174/1389201021666200416093457. View

18.

Zhang L, Chen W, Wang H, Liu C, He J, Tang Y . Growth factors regional patterned and photoimmobilized scaffold applied to bone tissue regeneration. J Mater Chem B. 2020; 8(48):10990-11000. DOI: 10.1039/d0tb02317e. View

19.

Li L, Wang X, Wang G, Zhao H . MiR-373 promotes the osteogenic differentiation of BMSCs from the estrogen deficiency induced osteoporosis. Eur Rev Med Pharmacol Sci. 2019; 23(17):7247-7255. DOI: 10.26355/eurrev_201909_18827. View

20.

Choi D, Cho S, Lee S, Choi C . The Beneficial Effects of Morusin, an Isoprene Flavonoid Isolated from the Root Bark of . Int J Mol Sci. 2020; 21(18). PMC: 7554996. DOI: 10.3390/ijms21186541. View